Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/200072
Type: Artigo de periódico
Title: Therapeutic Effectiveness Of Biosimilar Standard Interferon Versus Pegylated Interferon For Chronic Hepatitis C Genotypes 2 Or 3.
Author: Vigani, Aline Gonzalez
Gonçales, Eduardo Sellan
Pavan, Maria Helena Postal
Genari, Flavia
Tozzo, Raquel
Lazarini, Maria Silvia Kroll
Fais, Viviane
Feltrin, Adriana
Gonçales, Neiva Sellan
Gonçales Jr, Fernando Lopes
Abstract: Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 or 3, but its efficacy compared to Peg-IFN is unknown. To compare the sustained virological response (SVR) rates following treatment with biosimilar standard IFN plus ribavirin (RBV) versus Peg-IFN plus RBV in patients with HCV genotypes 2 or 3 infection. A retrospective cohort study was conducted in patients with HCV genotypes 2 or 3 infection treated with biosimilar standard IFN plus RBV or with Peg-IFN plus RBV. SVR rates of the two treatments were compared. From January 2005 to December 2010, 172 patients with a mean age of 44 +/- 9.3 years were included. There were eight (4.7%) patients with HCV genotype 2 infections. One hundred fourteen (66.3%) were treated with biosimilar standard IFN plus RBV, whist 58 (33.7%) patients were treated with Peg-IFN plus RBV. Between the two groups, there were no significant differences regarding age, gender, glucose level, platelet count, hepatic necroinflammatory grade, and hepatic fibrosis stage. Overall, 59.3% (102/172) patients had SVR. In patients treated with Peg-IFN plus RBV, 79.3% (46/58) had SVR compared to 49.1% (56/114) among those treated with biosimilar standard IFN plus RBV (p = 0.0001). In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV.
Subject: Adolescent
Adult
Aged
Antiviral Agents
Cohort Studies
Drug Therapy, Combination
Female
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Interferons
Male
Middle Aged
Polyethylene Glycols
Rna, Viral
Recombinant Proteins
Retrospective Studies
Ribavirin
Treatment Outcome
Viral Load
Young Adult
Rights: fechado
Identifier DOI: 
Address: http://www.ncbi.nlm.nih.gov/pubmed/22729189
Date Issue: -1-Uns- -1
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_22729189.pdf1.31 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.